Citi Pharma Receives Regulatory Clearance for Pakheim Acquisition

On 26 October, reports highlighted that Citi Pharma had received competition approval for its proposed acquisition of 100% of Pakheim International Pharma. The target company brings a portfolio of 63 branded products, supporting Citi Pharma’s strategy to expand beyond pharmaceutical ingredients into finished medicines. The acquisition price has not been publicly disclosed, and completion remains subject to outstanding legal and regulatory formalities. The proposed transaction reflects consolidation and expansion activity in Pakistan’s pharmaceutical sector. Investors and corporate-finance advisers can explore opportunities in transaction analysis, valuation modelling and post-acquisition integration planning. HPC can support these activities with financial analytics and secure data infrastructure; contact HPC for a quotation based on your project scope.